Synopsis
Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Schembl34274
2. Ft-0603494
3. Ft-0656045
Molecular Weight | 676.8 g/mol |
---|---|
Molecular Formula | C34H48N2O10S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 10 |
Exact Mass | 676.30296691 g/mol |
Monoisotopic Mass | 676.30296691 g/mol |
Topological Polar Surface Area | 191 Ų |
Heavy Atom Count | 47 |
Formal Charge | 0 |
Complexity | 415 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 6 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Atropine sulfate |
Drug Label | Atropine Sulfate Injection, USP is a sterile, nonpyrogenic isotonic solution of atropine sulfate monohydrate in water for injection with sodium chloride sufficient to render the solution isotonic. It is administered parenterally by subcutaneous, intr... |
Active Ingredient | Atropine sulfate |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 1% |
Market Status | Prescription |
Company | Akorn |
2 of 2 | |
---|---|
Drug Name | Atropine sulfate |
Drug Label | Atropine Sulfate Injection, USP is a sterile, nonpyrogenic isotonic solution of atropine sulfate monohydrate in water for injection with sodium chloride sufficient to render the solution isotonic. It is administered parenterally by subcutaneous, intr... |
Active Ingredient | Atropine sulfate |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 1% |
Market Status | Prescription |
Company | Akorn |
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Atropine Sulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Atropine Sulfate, including repackagers and relabelers. The FDA regulates Atropine Sulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Atropine Sulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Atropine Sulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Atropine Sulfate supplier is an individual or a company that provides Atropine Sulfate active pharmaceutical ingredient (API) or Atropine Sulfate finished formulations upon request. The Atropine Sulfate suppliers may include Atropine Sulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Atropine Sulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Atropine Sulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Atropine Sulfate active pharmaceutical ingredient (API) in detail. Different forms of Atropine Sulfate DMFs exist exist since differing nations have different regulations, such as Atropine Sulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Atropine Sulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Atropine Sulfate USDMF includes data on Atropine Sulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Atropine Sulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Atropine Sulfate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Atropine Sulfate Drug Master File in Japan (Atropine Sulfate JDMF) empowers Atropine Sulfate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Atropine Sulfate JDMF during the approval evaluation for pharmaceutical products. At the time of Atropine Sulfate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Atropine Sulfate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Atropine Sulfate Drug Master File in Korea (Atropine Sulfate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Atropine Sulfate. The MFDS reviews the Atropine Sulfate KDMF as part of the drug registration process and uses the information provided in the Atropine Sulfate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Atropine Sulfate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Atropine Sulfate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Atropine Sulfate suppliers with KDMF on PharmaCompass.
A Atropine Sulfate CEP of the European Pharmacopoeia monograph is often referred to as a Atropine Sulfate Certificate of Suitability (COS). The purpose of a Atropine Sulfate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Atropine Sulfate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Atropine Sulfate to their clients by showing that a Atropine Sulfate CEP has been issued for it. The manufacturer submits a Atropine Sulfate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Atropine Sulfate CEP holder for the record. Additionally, the data presented in the Atropine Sulfate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Atropine Sulfate DMF.
A Atropine Sulfate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Atropine Sulfate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Atropine Sulfate suppliers with CEP (COS) on PharmaCompass.
A Atropine Sulfate written confirmation (Atropine Sulfate WC) is an official document issued by a regulatory agency to a Atropine Sulfate manufacturer, verifying that the manufacturing facility of a Atropine Sulfate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Atropine Sulfate APIs or Atropine Sulfate finished pharmaceutical products to another nation, regulatory agencies frequently require a Atropine Sulfate WC (written confirmation) as part of the regulatory process.
click here to find a list of Atropine Sulfate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Atropine Sulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Atropine Sulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Atropine Sulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Atropine Sulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Atropine Sulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Atropine Sulfate suppliers with NDC on PharmaCompass.
Atropine Sulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Atropine Sulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Atropine Sulfate GMP manufacturer or Atropine Sulfate GMP API supplier for your needs.
A Atropine Sulfate CoA (Certificate of Analysis) is a formal document that attests to Atropine Sulfate's compliance with Atropine Sulfate specifications and serves as a tool for batch-level quality control.
Atropine Sulfate CoA mostly includes findings from lab analyses of a specific batch. For each Atropine Sulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Atropine Sulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Atropine Sulfate EP), Atropine Sulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Atropine Sulfate USP).
LOOKING FOR A SUPPLIER?